RANK Ligand/TNFSF11, Human, Recombinant <RANKL/TNFSF11> <TRANCE>

データシート

• 商品コード：390-TN-010
• メーカー：RSD
• 包装：10μg
• 価格： ¥67,000
• 在庫：無(未発注)

マイリストに追加 マイリストに追加済

• No.： 1
• 文献情報：
  Grimaud E et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am. J. Pathol. 2003 Nov;163(5):2021-31
  Grimaud E et al
  2003/01/01
  
• 備考：
  Sample Type: Serum
• 参照：
  

• No.： 2
• 文献情報：
  Chen G et al. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006 Jul;107(2):289-98
  Chen G et al
  2006/01/01
  
• 備考：
  Species: Human, Application: Bioassay, Whole Cells
• 参照：
  

• No.： 3
• 文献情報：
  Holding CA et al. The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials 2006 Oct;27(30):5212-9
  Holding CA et al
  2006/01/01
  
• 備考：
  Species: Human, Application: Control, Whole Tissue
• 参照：
  

• No.： 4
• 文献情報：
  Kawai T et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am. J. Pathol. 2006 Sep;169(3):987-98
  Kawai T et al
  2006/01/01
  
• 備考：
  Species: Mouse, Application: Bioassay, Sample type: Whole Cells
• 参照：
  

• No.： 5
• 文献情報：
  Koreny T et al. The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. Arthritis Rheum. 2006 Oct;54(10):3221-32
  Koreny T et al
  2006/01/01
  
• 備考：
  Species: Human, Application: Bioassay, Whole Cells
• 参照：
  

• No.： 6
• 文献情報：
  Tang CH et al. Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. J. Biol. Chem. 2007 Jan;282(4):2346-54
  Tang CH et al
  2007/01/01
  
• 備考：
  Application: Bioassay, Sample Type: Whole Cells
• 参照：
  

• No.： 7
• 文献情報：
  Colucci S et al. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J. Pathol. 2007 May;212(1):47-55
  Colucci S et al
  2007/01/01
  
• 備考：
  Species: Human, Application: Bioassay, Sample type: Whole Cells
• 参照：
  

• No.： 8
• 文献情報：
  Vitovski S et al. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J.
  Vitovski S et al
  2007/01/01
  
• 備考：
  Species: Human, Application: Bioassay, Sample type: recombinant protein
• 参照：
  

• No.： 9
• 文献情報：
  Boissy P et al. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leuk. Res. 2008 Nov;32(11):1661-8
  Boissy P et al
  2008/01/01
  
• 備考：
  Species: Human, Application: Bioassay, Whole Cells
• 参照：
  

• No.： 10
• 文献情報：
  Cadosch D et al. Titanium induced production of chemokines CCL17/TARC and CCL22/MDC in human osteoclasts and osteoblasts. J Biomed Mater Res A 2010 Feb;92(2):475-83
  Cadosch D et al
  2010/01/01
  
• 備考：
  Application: Bioassay, Sample Type: Whole Cells
• 参照：
  

• No.： 11
• 文献情報：
  S淡e K et al. Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle. J. Bone Miner. Res. 2010 Oct;25(10):2184-92
  S淡e K et al
  2010/01/01
  
• 備考：
  Application: Bioassay, Sample Type: Whole Cells
• 参照：
  

• No.： 12
• 文献情報：
  Wilson TR et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012 Jul;487(7408):505-9
  Wilson TR et al
  2012/01/01
  
• 備考：
  Application: Bioassay, Sample Type: Whole Cells
• 参照：
  

• No.： 13
• 文献情報：
  Cheng P et al. miR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene homolog B. J. Bone Miner. Res. 2013 May;28(5):1180-90
  Cheng P et al
  2013/01/01
  
• 備考：
  Application: Bioassay, Sample Type: Whole Cells
• 参照：
  

• No.： 14
• 文献情報：
  He W et al. Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma. FASEB J. 2013 Sep;27(9):3446-54
  He W et al
  2013/01/01
  
• 備考：
  Application: Bioassay, Sample Type: Whole Cells
• 参照：
  

• No.： 15
• 文献情報：
  Chen C et al. MiR-503 regulates osteoclastogenesis via targeting RANK. J. Bone Miner. Res. 2014 Feb;29(2):338-47
  Chen C et al
  2014/01/01
  
• 備考：
  Application: Bioassay, Sample Type: whole cells
• 参照：
  

• No.： 16
• 文献情報：
  Liu Z et al. Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression. PLoS ONE 2013;8(12):e82453
  Liu Z et al
  2013/01/01
  
• 備考：
  Application: Bioassay
• 参照：
  

• No.： 17
• 文献情報：
  T辿letch辿a S et al. Novel RANK antagonists for the treatment of bone-resorptive disease: theoretical predictions and experimental validation. J. Bone Miner. Res. 2014 Jun;29(6):1466-77
  T辿letch辿a S et al
  2014/01/01
  
• 備考：
  Application: Surface Plasmon Resonance, Sample Type: CM5 Sensor Chip
• 参照：
  

• No.： 18
• 文献情報：
  Yeon JT et al. Anti-osteoclastogenic activity of praeruptorin A via inhibition of p38/Akt-c-Fos-NFATc1 signaling and PLC&#x3B3;-independent Ca2+ oscillation. PLoS ONE 2014;9(2):e88974
  Yeon JT et al
  2014/01/01
  
• 備考：
  Application: Activity Assay, Sample Type: Whole Cells
• 参照：
  

• No.： 19
• 文献情報：
  Zheng Y et al. Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways. J. Bone Miner. Res. 2014 Sep;29(9):1938-49
  Zheng Y et al
  2014/01/01
  
• 備考：
  Application: Bioassay, Sample Type: Whole Cells
• 参照：
  

• No.： 20
• 文献情報：
  Alshbool FZ et al. Differential expression of claudin family members during osteoblast and osteoclast differentiation: Cldn-1 is a novel positive regulator of osteoblastogenesis. PLoS ONE 2014;9(12):e114357
  Alshbool FZ et al
  2014/01/01
  
• 備考：
  Application: Bioassay, Sample Type: Whole Cells
• 参照：
  

• No.： 21
• 文献情報：
  Zhu K et al. Impaired bone homeostasis in amyotrophic lateral sclerosis mice with muscle atrophy. J. Biol. Chem. 2015 Mar;290(13):8081-94
  Zhu K et al
  2015/01/01
  
• 備考：
  Application: Bioassay, Sample Type: Whole Cells
• 参照：
  

• No.： 22
• 文献情報：
  Kasonga AE et al. Arachidonic acid and docosahexaenoic acid suppress osteoclast formation and activity in human CD14+ monocytes, in vitro. PLoS ONE 2015;10(4):e0125145
  Kasonga AE et al
  2015/01/01
  
• 備考：
  Application: Bioassay, Sample Type: Whole Cells
• 参照：
  

• No.： 23
• 文献情報：
  Kalbasi Anaraki P et al. Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-&#x3BA;B pathway in osteoclasts. J. Bone Miner. Res. 2015 Feb;30(2):379-88
  Kalbasi Anaraki P et al
  2015/01/01
  
• 備考：
  Application: Bioassay, Sample Type: Whole Cells
• 参照：
  

• No.： 24
• 文献情報：
  Choi SW et al. Repositioning Potential of PAK4 to Osteoclastic Bone Resorption. J. Bone Miner. Res. 2015 Jan;
  Choi SW et al
  2015/01/01
  
• 備考：
  Application: Bioassay, Sample Type: Whole Cells
• 参照：
  

• No.： 25
• 文献情報：
  Savage JR et al. A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis. PLoS ONE 2016;11(6):e0157310
  Savage JR et al
  2016/01/01
  
• 備考：
  Application: Bioassay, Sample Type: protein
• 参照：